Catalyst Wire Dossier Catalyst Wire Dossier

Tivicay (dolutegravir)

dolutegravir · ViiV Healthcare
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Tivicay (dolutegravir), covering 2024-10-08 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone [NA]

See pricing